

1 **Humoral and cellular response induced by a second booster of an**

2 **inactivated SARS-CoV-2 vaccine in adults.**

3

4 Felipe Melo-González<sup>1,2,3#</sup>, Constanza Méndez<sup>1,2#</sup>, Hernán F Peñaloza<sup>1,2#</sup>, Bárbara  
5 M Schultz<sup>1,2#</sup>, Alejandro Piña-Iturbe<sup>1,2</sup>, Mariana Ríos<sup>1,2</sup>, Daniela Moreno-Tapia<sup>1,2</sup>,  
6 Patricia Pereira-Sánchez<sup>1,2</sup>, Diane Leighton<sup>1,2</sup>, Claudia Orellana<sup>1,2</sup>, Consuelo  
7 Covarrubias<sup>1,2</sup>, Nicolás MS Gálvez<sup>1,2</sup>, Jorge A Soto<sup>1,2,3</sup>, Luisa F Duarte<sup>1,2</sup>, Daniela  
8 Rivera-Pérez<sup>1,2</sup>, Yaneisi Vázquez<sup>1,2</sup>, Alex Cabrera<sup>4</sup>, Sergio Bustos<sup>4</sup>, Carolina  
9 Iturriaga<sup>5</sup>, Marcela Urzua<sup>5</sup>, María S Navarrete<sup>6</sup>, Álvaro Rojas<sup>6</sup>, Rodrigo Fasce<sup>7</sup>,  
10 Jorge Fernández<sup>7</sup>, Judith Mora<sup>7</sup>, Eugenio Ramírez<sup>7</sup>, Aracelly Gaete-Argel<sup>1,8</sup>, Mónica  
11 Acevedo<sup>1,8</sup>, Fernando Valiente-Echeverría<sup>1,8</sup>, Ricardo Soto-Rifo<sup>1,8</sup>, Daniela  
12 Weiskopf<sup>9</sup>, Alba Grifoni<sup>9</sup>, Alessandro Sette<sup>9,10</sup>, Gang Zeng<sup>11</sup>, Weining Meng<sup>11</sup>,  
13 CoronaVac03CL Study Group, José V González-Aramundiz<sup>12</sup>, Pablo A González<sup>1,2</sup>,  
14 Katia Abarca<sup>1,5</sup>, Susan M Bueno<sup>\*,1,2</sup>, Alexis M Kalergis<sup>\*,1,2,13</sup>.

15

16 <sup>1</sup>Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.

17 <sup>2</sup>Departamento de Genética Molecular y Microbiología, Facultad de Ciencias

18 Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile. <sup>3</sup>Departamento

19 de Ciencias Biológicas, Facultad de Ciencias de la Vida, Universidad Andrés Bello,

20 Santiago, Chile. <sup>4</sup>Flow Cytometry Facility, Facultad de Ciencias Biológicas, Pontificia

21 Universidad Católica de Chile, Santiago, Chile. <sup>5</sup>Departamento de Enfermedades

22 Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina,

23 Pontificia Universidad Católica de Chile, Santiago, Chile. <sup>6</sup>Departamento de

24 Enfermedades Infecciosas del Adulto, División de Medicina, Escuela de Medicina,

25 Pontificia Universidad Católica de Chile, Santiago, Chile. <sup>7</sup>Departamento de  
26 Laboratorio Biomédico, Instituto de Salud Pública de Chile. <sup>8</sup>Laboratorio de Virología  
27 Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas,  
28 Facultad de Medicina, Universidad de Chile, Santiago de Chile. <sup>9</sup>Center for  
29 Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI),  
30 La Jolla, CA 92037, USA. <sup>10</sup>Department of Medicine, Division of Infectious Diseases  
31 and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA  
32 92037, USA. <sup>11</sup>Sinovac Biotech, Beijing, China. <sup>12</sup>Departamento de Farmacia,  
33 Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile,  
34 Santiago, Chile. <sup>13</sup>Departamento de Endocrinología, Facultad de Medicina, Escuela  
35 de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

36

37 **\*Corresponding author:**

38 Alexis M Kalergis, Pontificia Universidad Católica de Chile. Av. Libertador Bernardo  
39 O'Higgins N° 340, Santiago 8331010, Santiago, Chile. Phone 56-2-6862846. Email:  
40 [akalergis@bio.puc.cl](mailto:akalergis@bio.puc.cl).

41 **\*Alternate corresponding author:**

42 Susan M Bueno, Pontificia Universidad Católica de Chile. Av. Libertador Bernardo  
43 O'Higgins N° 340, Santiago 8331010, Santiago, Chile. Phone 56-2-6862846. Email:  
44 [sbueno@bio.puc.cl](mailto:sbueno@bio.puc.cl)

45

46 **#These authors contributed equally to this work.**

47 **Summary**

48 The SARS-CoV-2 Omicron variant has challenged the control of the COVID-19  
49 pandemic even in highly vaccinated countries. While a second booster of mRNA  
50 vaccines improved the immunity against SARS-CoV-2, the humoral and cellular  
51 responses induced by a second booster of an inactivated SARS-CoV-2 vaccine have  
52 not been studied. In the context of a phase 3 clinical study, we report that a second  
53 booster of CoronaVac<sup>®</sup> increased the neutralizing response against the ancestral  
54 virus yet showed poor neutralization against the Omicron variant. Additionally,  
55 isolated PBMCs displayed equivalent activation of specific CD4<sup>+</sup> T cells and IFN- $\gamma$   
56 production when stimulated with a mega-pool of peptides derived from the spike  
57 protein of the ancestral virus or the Omicron variant. In conclusion, a second booster  
58 dose of CoronaVac<sup>®</sup> does not improve the neutralizing response against the  
59 Omicron variant compared with the first booster dose, yet it helps maintaining a  
60 robust spike-specific CD4<sup>+</sup> T cell response.

61

62 **Key words:** CoronaVac<sup>®</sup>, second booster dose, SARS-CoV-2, Omicron variant,  
63 humoral immunity, cellular immunity.

64 **Introduction.**

65 The development of vaccines that grant long-lasting protection against SARS-CoV-  
66 2 is essential to control the current COVID-19 pandemic. Although several vaccines  
67 were developed in record time, three dynamic phenomena have prevented the global  
68 control of the COVID-19 pandemic. First, the continuous emergence of SARS-CoV-  
69 2 variants of concern (VOCs), such as Omicron (BA.1, BA.2), and its subvariants  
70 (BA.2.12.1, BA.4, BA.5) with high transmissibility and immune evasion profiles<sup>1</sup>.  
71 Second, the waning of neutralizing antibodies in fully vaccinated subjects<sup>2</sup>. Third, the  
72 difficulties to mass producing and globally distributing enough vaccines or  
73 implementing affordable and effective vaccination programs.

74 Several platforms have been used to develop vaccines against SARS-CoV-2<sup>3</sup>. Due  
75 to their novelty, mRNA vaccines (BNT162b2 and mRNA-1273) have been the most  
76 studied and are highly effective in protecting individuals from symptomatic infection,  
77 severe disease, and death<sup>4,5</sup>. Inactivated virus-based vaccine, a more traditional  
78 vaccine platform, has also been used to develop a SARS-CoV-2 vaccine.  
79 CoronaVac<sup>®</sup>, an inactivated vaccine developed by Sinovac Life Sciences Co., Ltd.  
80 (Beijing, China)<sup>6</sup>, has been administered so far in 52 countries<sup>7</sup>, showing a good  
81 safety profile in the population<sup>8-10</sup> and a robust immune protection against severe  
82 disease, hospitalization, and death<sup>11</sup>.

83 During a phase 3 clinical trial in Chile, our group demonstrated that a two-dose  
84 vaccination schedule of CoronaVac<sup>®</sup> induced a strong neutralizing response and T  
85 cell activation against SARS-CoV-2 in adults<sup>12</sup>. Further studies from our laboratory  
86 determined that fully vaccinated subjects with CoronaVac<sup>®</sup> showed a strong  
87 production of neutralizing antibodies and IFN- $\gamma$  production in stimulated peripheral

88 blood mononuclear cells (PBMCs) against different VOCs of SARS-CoV-2, such as  
89 Alpha, Beta, Gamma, and Delta<sup>13</sup>.

90 Different studies have reported a reduction of the neutralizing response against  
91 SARS-CoV-2 in immunized subjects with BNT162b2 and mRNA1273 vaccines<sup>14-16</sup>.

92 These studies also showed that a booster dose was required to keep an effective  
93 neutralizing response against the ancestral SARS-CoV-2 (WT SARS-CoV-2) and  
94 circulating variants at that time<sup>14,15,17</sup>.

95 Consistently with the mentioned studies, our group reported a considerable  
96 reduction of the neutralizing response five months after the administration of the  
97 second dose of CoronaVac<sup>®</sup>, response that was recovered after the administration  
98 of a booster dose of CoronaVac<sup>®</sup><sup>18</sup>. Furthermore, the enhanced neutralizing  
99 response initially detected against WT SARS-CoV-2 was effective against the Delta  
100 variant, but showed reduced neutralization against the Omicron variant<sup>18</sup>, which is  
101 currently the most prevalent variant of SARS-CoV-2 worldwide.

102 Although previous studies have shown that a second booster with BNT162b2 and  
103 mRNA1273 vaccines would prevent the decrease of neutralizing antibodies and may  
104 offer protection against symptomatic disease, severe disease, hospitalization, and  
105 death caused by the Omicron variant<sup>4,19</sup>, the effect of a second booster dose of  
106 CoronaVac<sup>®</sup> in the humoral and cellular response against SARS-CoV-2, with special  
107 emphasis on the Omicron variant, remains to be elucidated. In the present report,  
108 we study the dynamics of the humoral and cellular immune responses in individuals  
109 that received a second booster of CoronaVac<sup>®</sup> 6 months after the administration of  
110 a first booster of the same vaccine. Our data shows that a second booster of  
111 CoronaVac<sup>®</sup> induces a strong production of antibodies with neutralizing capacities

112 against WT SARS-CoV-2, although it has poor activity against the Omicron variant.

113 We also show that a second booster dose of CoronaVac<sup>®</sup> is required to keep high

114 levels of SARS-CoV-2-specific CD4<sup>+</sup> T cells in circulation that are reactive against

115 the WT SARS-CoV-2, the Delta, and the Omicron variants.

116

117 **Results.**

118 **1. Participants, sampling and experimental applications included in the study.**

119 From a total of 2,302 individuals enrolled in the clinical trial CoronaVac03CL  
120 (clinicaltrials.gov #NCT04651790) in Chile (November 2020- to current date)  
121 <sup>12,13,18,20,21</sup>, 138 fully vaccinated subjects with CoronaVac<sup>®</sup> (0-28 schedule) that  
122 received two booster doses were initially considered for this study (Fig 1A). After the  
123 exclusion of 51 subjects due to SARS-CoV-2 infection during the trial or missing  
124 data, longitudinal analyses of the humoral response were performed in up to 87  
125 subjects, whereas the cellular response was studied in a subgroup of 46 subjects  
126 (Fig 1A).

127 Blood samples were collected before vaccination (T1), four to seven weeks after the  
128 second dose (T2), at least 9 weeks before the first booster dose (T3), three to six  
129 weeks after the first booster dose (T4), at least nine to zero weeks before the second  
130 booster dose (T5) and four to nine weeks after second booster dose (T6) (Fig 1B).

131

132 **2. Humoral response against SARS-CoV-2 induced by a second booster dose**  
133 **of CoronaVac<sup>®</sup>.**

134 Neutralizing response of serum was evaluated by three different and complementary  
135 methodologies, surrogate virus neutralization test (sVNT), conventional virus  
136 neutralization test (cVNT), and pseudotype virus neutralization test (pVNT) (see  
137 method section). Consistently with previous studies<sup>12,18</sup>, individuals vaccinated with  
138 two doses of CoronaVac<sup>®</sup> presented a significant increase in neutralizing antibodies  
139 against WT SARS-CoV-2 four weeks after the administration of the second dose  
140 when compared with the pre-immune serum (T1 vs. T2) (16.8 vs. 199.7 GMUs

141 p<0.0001; 2.9 vs. 21.1 GMTs p<0.0001) (Fig. 2A-B, supplementary tables 1 and 3).  
142 Then, a significant reduction in the neutralizing antibody against SARS-CoV-2 was  
143 observed three to five months (15-20 weeks) after the administration of the second  
144 dose when compared with four weeks after the administration of the second dose  
145 (T2 vs. T3) (199.7 vs. 53.1 GMUs p<0.0001; 21.1 vs. 10.0 GMTs p<0.0001) (Fig.  
146 2A-B supplementary table 1 and 3). Consistently with other studies<sup>14-16</sup>, the  
147 administration of a first booster dose resulted in a rapid improvement of the  
148 neutralizing response against WT SARS-CoV-2 after 4 weeks when compared with  
149 at least nine weeks before its administration (T3 vs. T4) (53.1 vs. 586.0 GMUs  
150 p<0.0001; 10.0 vs. 95.1 GMTs p<0.0001) (Fig. 2A-B supplementary table 1 and 3).  
151 Interestingly, the neutralizing capacity against WT SARS-CoV-2 observed six  
152 months (24 weeks) after the administration of the first booster dose was partially  
153 reduced in comparison to the response detected 4 weeks after the administration of  
154 the first booster dose (T5 vs. T4) (220.4 vs. 586.0 GMUs p<0.001; 54.9 vs.  
155 95.1 GMTs p>0.05) (Fig. 2A-B, supplementary table 1 and 3). Finally, 4 to 9 weeks  
156 after the administration of a second booster dose, an increase in the neutralizing  
157 response against WT SARS-CoV-2 was observed when compared with the time  
158 before the administration of the second booster dose (T5 vs. T6) (220.4 vs. 549.2  
159 GMUs p<0.001; 54.9 vs. 149.3 GMTs p>0.05) (Fig. 2A-B, supplementary table 1 and  
160 3). Importantly, the neutralization response against WT SARS-CoV-2 observed after  
161 the administration of the second booster dose was not significantly higher than the  
162 response induced by the first booster dose (T4 vs. T6) (586.0 vs. 549.2 GMUs  
163 p>0.05; 95.1 vs. 149.3 GMTs p>0.05) (Fig. 2A-B, supplementary table 1 and 3). This  
164 data indicates that a second booster dose of CoronaVac<sup>®</sup> is required to keep high



165 levels of neutralizing antibodies against WT SARS-CoV-2. Moreover, given that the  
166 neutralization observed after the first and the second booster dose was equivalent,  
167 we hypothesize that the neutralizing response against SARS-CoV-2 induced by the  
168 administration of the first booster dose of CoronaVac<sup>®</sup> has reached a peak of  
169 neutralizing antibodies that are sustained by the administration of a second booster  
170 dose.

171 The administration of the second booster dose of CoronaVac<sup>®</sup> kept the seropositivity  
172 rate higher than 96% for both sVNT and cVNT, with seroconversion levels of 93.1%  
173 and 95.2% for sVNT and cVNT, respectively (supplementary table 3).

174 Next, we evaluated whether the neutralizing antibodies generated after the second  
175 booster dose was effective against the Delta (B.1.617.2) and the Omicron  
176 (B.1.1.529) variants. Although serum from vaccinated individuals collected four  
177 weeks after the second booster dose presented a mildly reduced ability to neutralize  
178 WT SARS-CoV-2 when compared with samples collected four weeks after the first  
179 booster dose (Fig 2C), the neutralization response against WT SARS-CoV-2 was  
180 significantly higher when compared with the Delta (B.1.617.2) and especially with  
181 the Omicron (B.1.1.529) variants (33.0 vs. 3.7 GMTs  $p < 0.001$ , 8.9-fold reduction)  
182 (Fig 2C, supplementary table 2). Moreover, as compared with the first booster dose,  
183 the administration of the second booster dose of CoronaVac<sup>®</sup> did not significantly  
184 impact the seropositivity rate (93.1% vs. 94.3%) and the seroconversion rate (80.5%  
185 vs. 67.8%) against the Delta variant, although it slightly increased the seropositivity  
186 rate (17.2% vs. 32.2%) and the seroconversion rate (4.6% vs. 18.4%) against the  
187 Omicron variant (supplementary table 4).

188 Neutralization against the Omicron variant was also confirmed with a pseudotype-  
189 based neutralization assay in sixty subjects (supplementary figure 1) and indicate  
190 that a second booster dose of CoronaVac<sup>®</sup> maintains high neutralizing antibody  
191 levels against WT SARS-CoV-2 that reduced neutralization capacity against the  
192 Omicron variant.

193

194 **3. Cellular response against SARS-CoV-2 induced by a second booster dose**  
195 **of CoronaVac<sup>®</sup>.**

196 We next evaluated the cellular response in a subgroup of fully vaccinated volunteers  
197 (n=46) that received two booster doses of CoronaVac<sup>®</sup> (Fig 1A). PBMCs were  
198 stimulated with mega-pools of peptides of SARS-CoV-2 theoretically able to activate  
199 CD4<sup>+</sup> T cells (S+R) and CD8<sup>+</sup> T cells (CD8A+B)<sup>22</sup> and SARS-CoV-2-specific  
200 OX40<sup>+</sup>CD137<sup>+</sup>CD4<sup>+</sup>T cells (AIM<sup>+</sup>CD4<sup>+</sup> T cells), as well as SARS-CoV-2 specific  
201 CD69<sup>+</sup>CD137<sup>+</sup>CD8<sup>+</sup> T cells (AIM<sup>+</sup>CD8<sup>+</sup> T cells) were quantified by flow cytometry.

202 Our data show that the activation of SARS-CoV-2-specific AIM<sup>+</sup>CD4<sup>+</sup> T cells was  
203 higher after the second dose of CoronaVac<sup>®</sup> in comparison with the pre-immune  
204 sample (0.13% vs. 0.33% p=0.0241) (Fig. 3A; supplementary table 5). Although no  
205 significant increase in the percentage of AIM<sup>+</sup>CD4<sup>+</sup> T cells was observed after the  
206 administration of the first or the second booster dose, the activation of AIM<sup>+</sup>CD4<sup>+</sup> T  
207 cells remained stable over time, showing only a significant decrease 4-6 months  
208 after the first booster dose, that is successfully recovered after the administration of  
209 the second booster dose (Fig 3A, supplementary table 5). Further, we did not detect  
210 a significant activation of SARS-CoV-2-specific AIM<sup>+</sup>CD8<sup>+</sup> T cells in fully vaccinated

211 volunteers with CoronaVac<sup>®</sup> after the administration of the first or the second booster  
212 dose (Fig. 3B; supplementary table 5).

213 Next, we evaluated the production of IFN- $\gamma$  in stimulated-PBMCs by ELISPOT (Fig.  
214 3C-D, supplementary table 5). The production of IFN- $\gamma$  by stimulated PBMCs was  
215 consistent with the activation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in subjects that received a  
216 second booster dose of CoronaVac<sup>®</sup>. A significant increase in IFN- $\gamma$ <sup>+</sup> SFCs was  
217 observed in PBMCs stimulated with MP-S+R after the second dose of CoronaVac<sup>®</sup>  
218 (4.1-fold increase in PBMCs stimulated with MP-S+R  $p=0.0004$ ) (Fig 3C,  
219 supplementary table 5). Moreover, the increase in IFN- $\gamma$ <sup>+</sup>SFCs observed after the  
220 second dose of CoronaVac<sup>®</sup> remained stable over time and was also observed after  
221 the administration of the first and the second booster dose (Fig 3C, supplementary  
222 table 5). In contrast, no significant changes in IFN- $\gamma$ <sup>+</sup>SFCs were observed in PBMCs  
223 stimulated with MP-CD8A+B after the second dose of CoronaVac<sup>®</sup> (1.5-fold increase  
224 in PBMCs stimulated with MP-CD8A+B  $p>0.05$ ) (Fig. 3D) nor after the administration  
225 of a first or second booster of CoronaVac<sup>®</sup> (Fig 3D, supplementary table 5).

226 Even though we did not detect a significant increase in the frequency of AIM<sup>+</sup>CD4<sup>+</sup>T  
227 cells after the administration of the first or the second booster doses of CoronaVac<sup>®</sup>,  
228 we observed important changes in the frequency of volunteers with detectable levels  
229 of AIM<sup>+</sup>CD4<sup>+</sup>T cells over time. Whereas 13.0% (6/46) of volunteers presented  
230 detectable levels of SARS-CoV-2-specific AIM<sup>+</sup>CD4<sup>+</sup>T cells before vaccination, two  
231 doses of CoronaVac<sup>®</sup> increased this frequency to 34.8% (16/46), frequency that was  
232 further increased after the first booster of CoronaVac<sup>®</sup>, where 65.2% (30/46) of  
233 subjects showed detectable levels of SARS-CoV-2-specific AIM<sup>+</sup>CD4<sup>+</sup>T cells (Table  
234 1). Consistently, the frequency of subjects whose PBMCs produced IFN- $\gamma$  after

235 stimulation with MP-S+R increased after the administration of CoronaVac<sup>®</sup>, starting  
236 from 17.4% (8/46) before vaccination to 47.8% (22/46) after two doses of  
237 CoronaVac<sup>®</sup> and to 67.4% (31/46) after the first booster of CoronaVac<sup>®</sup> (Table 1).  
238 Interestingly, the second booster of CoronaVac<sup>®</sup> (45.7%, 21/46) did not increase the  
239 frequency of volunteers that have specific SARS-CoV-2 specific AIM<sup>+</sup>CD4<sup>+</sup>T cells in  
240 circulation as compared with the first booster dose, although it seems that it is  
241 required to prevent the decrease in frequency of volunteers with SARS-CoV-2  
242 specific AIM<sup>+</sup>CD4<sup>+</sup>T cells observed right before the administration of the second  
243 booster dose (41.3%, 19/46) (Table 1). Moreover, the second booster of  
244 CoronaVac<sup>®</sup> did not significantly affect the progressive decrease of IFN- $\gamma$  production  
245 by stimulated PMBCs (50% 23/46) in comparison with the response induced by the  
246 first booster dose, where 67.4% of the volunteers (31/46) showed production IFN- $\gamma$   
247 production (Table 1).

248 A mild increase in the frequency of volunteers that showed AIM<sup>+</sup>CD8<sup>+</sup> T cells after  
249 two doses of CoronaVac<sup>®</sup> (34.8%, 16/46) was observed as compared to before  
250 vaccination (13.0%, 6/46) (Table 1). Even though the administration of a first booster  
251 of CoronaVac<sup>®</sup> (34.8%, 16/46) was necessary to keep the frequency of volunteers  
252 with detectable levels of SARS-CoV-2-specific AIM<sup>+</sup>CD8<sup>+</sup> T cells, the second booster  
253 dose (26.1%, 12/46) did not prevent the reduction of the positivity of SARS-CoV-2-  
254 specific AIM<sup>+</sup>CD8<sup>+</sup> T cells in our cohort (Table 1). In addition, when PBMCs were  
255 stimulated with MP-CD8A+B, the frequency of volunteers that showed IFN- $\gamma$   
256 production reached a peak of 17.4% (8/46) right before the administration of a  
257 second booster that slightly decreased after the administration of the second booster  
258 dose of CoronaVac<sup>®</sup> (13.0%, 6/46) (Table 1).

259 Finally, we evaluated the activation of AIM<sup>+</sup>CD4<sup>+</sup> T cells and IFN- $\gamma$ <sup>+</sup> production by  
260 PBMCs in response to a mega-pool of peptides derived from the Spike protein of the  
261 Delta and the Omicron variants by flow cytometry and ELISPOT, respectively, four  
262 weeks after the administration of the first booster dose and four weeks after the  
263 administration of the second booster dose. Our data show that the activation  
264 AIM<sup>+</sup>CD4<sup>+</sup> T cells and IFN- $\gamma$ <sup>+</sup>SFCs were equivalent when PBMCs were stimulated  
265 with a mega-pool of peptides derived from the WT SARS-CoV-2, the Delta, or the  
266 Omicron variants (Fig. 3E-F) and no major differences were detected in the  
267 activation of AIM<sup>+</sup>CD4<sup>+</sup> T cells and IFN- $\gamma$ <sup>+</sup>SFCs in PBMCs, between the first and the  
268 second booster dose against each of these variants (Fig. 3E-F). Importantly, we  
269 detected a small decrease in the percentage of subjects that presented Spike-  
270 specific CD4<sup>+</sup>AIM<sup>+</sup> against the WT, Delta and Omicron variants after the second  
271 booster compared with after the first booster dose (supplementary table 6).  
272 Importantly, the frequency of volunteers whose PBMCs produced IFN- $\gamma$  remained  
273 constant after the stimulation of MP-S from WT and the Delta variant and only  
274 showed a mild decreased after MP-S from the Omicron variant (supplementary table  
275 6).

276 These data show that CoronaVac<sup>®</sup> induces a robust CD4<sup>+</sup> T cells response able to  
277 react against the Delta and the Omicron variants that remains high after a second  
278 booster dose even though it showed a progressive decrease in its positivity.  
279 Although the humoral immunity against Delta and Omicron variants decreases,  
280 cellular immunity remains robust across time and reacts against these variants.

281

282 **Discussion.**

283 In line with other reports<sup>4,19</sup>, our data show that a second booster dose of  
284 CoronaVac<sup>®</sup> restores the neutralizing response against the RBD of SARS-CoV-2 to  
285 similar levels reached after the administration of the first booster dose.

286 Neutralizing antibodies induced by vaccines has been acknowledged as the first line  
287 of defense against SARS-CoV-2 infection. However, follow-up studies have shown  
288 that fully vaccinated individuals show a gradual decrease in their levels of circulating  
289 neutralizing antibodies over time<sup>14-16,18</sup>. This response can be restored with the  
290 administration of a booster dose<sup>14,18</sup>, and some studies have even shown that a  
291 second booster dose may grant better protection against severe disease,  
292 hospitalization, and death due to COVID-19<sup>4,23</sup>.

293 Our data show that despite a second booster dose induces the production of  
294 neutralizing antibodies against WT SARS-CoV-2, these antibodies only weakly  
295 neutralized the Omicron variant. These results are consistent with other studies that  
296 show that the Omicron variant and its subvariants are incredibly efficient in evading  
297 serum neutralization from individuals who have received one or two booster  
298 doses<sup>1,19,24</sup>. Therefore, it is unlikely that nowadays, the increased protection against  
299 severe disease, hospitalization, and death granted by a second booster dose could  
300 be mainly mediated by the action of neutralizing antibodies.

301 Nonetheless, we detected a slight but non-significant increment of 1.6-fold change  
302 in the neutralization of WT SARS-CoV-2 between four weeks after the first booster  
303 dose and four weeks after the second booster dose by cVNT (Fig 1B). This modest  
304 increase in WT SARS-CoV-2 neutralization granted by the second booster was not  
305 observed through sVNT (Fig 1A, C). sVNT directly neutralizes the binding of the RBD  
306 with ACE-2, neglecting the potential role of neutralizing antibodies against other

307 portions of the Spike protein and even against other viral proteins. Therefore, it is  
308 possible that neutralizing antibodies against other domains of the Spike protein and  
309 potentially against other viral proteins such as the membrane or the nucleocapsid  
310 proteins not considered in the sVNT approach may actively participate in viral  
311 neutralization.

312 The second layer of protection corresponds to the proliferation, activation, and  
313 activity of T cells. Currently, the leading hypothesis regarding the protective  
314 mechanism of SARS-CoV-2 vaccines against severe disease and death relies on  
315 the induction of long-lasting T cells responses rather than on the availability of  
316 circulating neutralizing antibodies<sup>25,26</sup>.

317 In the present study, we report that the activation of AIM<sup>+</sup>CD4<sup>+</sup> T cells in fully  
318 vaccinated individuals remains detectable over time after administering a first and a  
319 second booster of CoronaVac<sup>®</sup>. In addition, one study has identified a robust  
320 activation of CD4<sup>+</sup>OX40<sup>+</sup>CD137<sup>+</sup> T cells, CD4<sup>+</sup>OX40<sup>+</sup>sCD40L<sup>+</sup> T cells, and follicular  
321 CD4<sup>+</sup>CXCR5<sup>+</sup>OX40<sup>+</sup> T cells in individuals that received two doses of mRNA-1273,  
322 BNT162b2 or NVX-CoV2373 (Novavax), and one dose of Ad26.COVS.2.S  
323 (Janssen)<sup>27</sup>. Our data is consistent with these findings, although the ability of  
324 CoronaVac<sup>®</sup> to induce a robust memory T cell response remains to be elucidated.

325 On the other hand, it has been reported a significant expansion and activation of  
326 IFN- $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells in PBMCs of individuals vaccinated with two doses of mRNA-  
327 1273, BNT162b2, and NVX-CoV2373, and one dose of Ad26.COVS.2.S<sup>27</sup>. However,  
328 we did not find a significant increase in CD8<sup>+</sup>AIM<sup>+</sup> T cells (Fig. 3B) nor a significant  
329 increase in IFN- $\gamma$  production (Fig 3D) in stimulated PBMCs from subjects immunized  
330 with CoronaVac<sup>®</sup> when compared with the pre-immune sample. In contrast, previous

331 studies have described that two doses of CoronaVac<sup>®</sup> induce the production of IFN-  
332  $\gamma$  by CD8<sup>+</sup> T cells<sup>28,29</sup>. Therefore, more exhaustive studies aimed to understand how  
333 CoronaVac<sup>®</sup> influences the expansion and activation of CD8<sup>+</sup> T cells, memory T  
334 cells, and memory B cells are required to fully elucidate the protective mechanisms  
335 driven by CoronaVac<sup>®</sup> in immunized adults, children, and the elderly.

336 Four interesting findings emerge from our study. First is the presence of neutralizing  
337 antibodies (Fig 2A-B) in pre-immune samples of some individuals. Most of the pre-  
338 immune neutralizing response was identified against the infective virus.  
339 Asymptomatic SARS-CoV-2 infections<sup>30</sup> and antibodies generated against non-  
340 spike proteins of seasonal coronaviruses<sup>31</sup> could explain this response, although  
341 serologic studies are needed to confirm these hypotheses. Moreover, our data show  
342 that whereas 6/46 of the analyzed volunteers presented SARS-CoV-2-specific  
343 AIM<sup>+</sup>CD4<sup>+</sup> or AIM<sup>+</sup>CD8<sup>+</sup> T cells before the administration of CoronaVac<sup>®</sup>; 25/46 and  
344 34/46 volunteers did not present AIM<sup>+</sup>CD4<sup>+</sup> or AIM<sup>+</sup>CD8<sup>+</sup> T cells, respectively after  
345 the second booster of CoronaVac<sup>®</sup>. A previous study has shown a possible cross-  
346 reactive response of seasonal coronaviruses-specific T cells against SARS-CoV-2<sup>22</sup>,  
347 and it is likely the reason why some volunteers presented SARS-CoV-2 specific T  
348 cells before vaccination, although asymptomatic infections cannot be ruled out.  
349 Further studies are needed to fully understand the factors involved in the generation  
350 and maintain of an efficient T cell response and the effect on vaccine-induced  
351 protection.

352 Finally, our data show that the effect on humoral and cellular responses of the  
353 second booster dose, is different when compared with the effect of the first booster  
354 dose. Whereas our data and several other studies have shown that a first booster



355 increase the humoral and cellular response against SARS-CoV-2<sup>14,15,17,18</sup>, the  
356 administration of a second booster dose seems to maintain the global neutralizing  
357 response, the activation of AIM<sup>+</sup>CD4<sup>+</sup> T cells and IFN- $\gamma$  by stimulated PBMCs  
358 against WT SARS-CoV-2 and the Omicron variant reached by the first booster dose.  
359 Importantly, in terms of the percentage of individuals able to respond against the  
360 virus, our data show that even though the second booster restores seropositivity and  
361 seroconversion to equivalent levels observed after the first booster dose, it seems  
362 to be insufficient to restore the frequency of volunteers with detectable SARS-CoV-  
363 2-specific AIM<sup>+</sup>CD4<sup>+</sup> T cells and IFN- $\gamma$  by stimulated PBMCs to levels observed after  
364 the first booster dose.

365 Controlling the COVID-19 pandemic requires multiple efforts to prevent severe  
366 disease and death of infected patients and reduce viral infection and circulation in  
367 the community.

368 The data provided in this report and other studies suggest that CoronaVac<sup>®</sup> and  
369 other current vaccines effectively protect the population from severe disease,  
370 hospitalization, and death. However, the immune response induced by these  
371 vaccines poorly neutralizes the circulating SARS-CoV-2 variants and cannot prevent  
372 viral infection.

373 Therefore, new strategies that include the design of new vaccines that target the  
374 current variants, new types of vaccines that enforce immunity in the upper respiratory  
375 tract, and global vaccine distribution programs are essential to control and end the  
376 COVID-19 pandemic.

377 **Methods.**

378 **Volunteers and sample collection**

379 Blood samples were obtained from volunteers recruited in the clinical trial  
380 CoronaVac03CL (clinicaltrials.gov #NCT04651790) in Chile (November 2020- to  
381 current date)<sup>12,13,18,20,21</sup>.

382 Of the 2,302 individuals enrolled at baseline, 409 subjects entered the study and  
383 received two doses with the homologous CoronaVac<sup>®</sup> 0-28 schedule, and 138  
384 subjects ended up receiving two booster doses of CoronaVac<sup>®</sup>. In addition, blood  
385 samples from 87 subjects were collected from before vaccination (T0) to up to four-  
386 nine weeks after the second booster administration (T6). Volunteers who did not  
387 have a blood sample at some of the planned times of the study or who had previously  
388 exceeded the definitive time limit and volunteers who had developed SARS-COV-2  
389 during the study were excluded (Figure 1A).

390 Volunteers received two doses of CoronaVac<sup>®</sup> (3 µg or 600SU of inactivated SARS-  
391 CoV-2 inactivated in the presence of alum adjuvant) in a four-week interval (0-28  
392 days), a booster dose five months after the second dose, and a second booster dose  
393 6 months after the first (Figure 1B). Blood samples collected 6 times were analyzed:  
394 T1: Pre-immune, T2: 2<sup>nd</sup> dose + 4 weeks (+3 weeks), T3: before the administration  
395 of the third dose (-9 weeks), T4: at 4 weeks ( $\pm$ 2 weeks) after the third dose, T5:  
396 before the administration of the fourth dose (-9 weeks), T6: and at 4 weeks (+5  
397 weeks) after the fourth dose (T6), and vaccination schedule.

398

399 **Experimental procedures**

400 Neutralizing antibodies against RBD of WT SARS-CoV-2 were measured in the  
401 serum of 87 volunteers recruited in the clinical trial CoronaVac03CL (clinicaltrials.gov  
402 #NCT04651790). Briefly, blood samples were obtained at T1, T2, T3, T4, T5, and  
403 T6. Neutralization of SARS-CoV-2 RBD by circulating antibodies at each time point  
404 was evaluated by a surrogate virus neutralization test (sVNT) (Genscript  
405 Cat#L00847-A)<sup>12</sup>. The antibody levels in international units per mL (IU/mL) were  
406 estimated by interpolating the sVNT absorbance data in the standard curve made  
407 with the WHO International Standard 20/136, using the 4-parameter Logistic model.  
408 In addition, sVNT was used to evaluate the neutralizing capacity of the tools against  
409 the Delta and Omicron variants, the RBDs for the S protein of SARS-CoV-2 for Delta  
410 (Cat# Z03516) and Omicron B.1.1.529 (Cat#Z03730) in 87 volunteers.  
411 Infective virus neutralization assays were performed as previously described<sup>12,18</sup>.  
412 Briefly, Vero E6 cells ( $4 \times 10^4$  cells/well) were plated in 96-well plates. 100  $\mu$ L of  
413 33782CL-SARS-CoV-2 (100 TCID<sub>50</sub>) were incubated with serial dilutions of heat-  
414 inactivated individual serum samples (dilutions of 1:4, 1:8, 1:16, 1:32, 1:64, 1:128,  
415 1:256, and 1:512) for 1h at 37 °C. Then, the mix was added to the 96-well plates with  
416 the Vero E6 cells, and the cytopathic effect was analyzed after 7 days. A serum  
417 sample from uninfected patients (negative control) and a neutralizing COVID-19  
418 patient serum sample (positive control) was used for each test.  
419 A pseudotyped virus neutralization test (pVNT) assay was performed to assess the  
420 capacity of the antibodies against SARS-CoV-2 VOC in samples from forty-eight  
421 volunteers as previously reported<sup>32</sup>. Briefly, a HIV-1 backbone expressing firefly  
422 luciferase as a reporter gene and pseudotyped with the SARS-CoV-2 spike  
423 glycoproteins (HIV-1-S $\Delta$ 19) from lineage B.1 (D614G) and variant Omicron (A67V,

424  $\Delta$ H69-V70, T95I, Y145D,  $\Delta$ G142 -V143- Y144,  $\Delta$ N211, EPE 213-214, G339D,  
425 S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R,  
426 G496S, Q498R, N501Y, T547K, D614G, H655Y, N679K, P681H, N764K, N865K,  
427 Q954H, N969K, L981F) was prepared. Serum samples were diluted, and the  
428 estimation of the ID<sub>80</sub> was obtained using a 4-parameter nonlinear regression curve  
429 fit measured as the percent of neutralization determined by the difference in average  
430 relative light units (RLU) between test samples and pseudotyped virus controls.  
431 Seropositivity is considered when titers are increased compared to pre-immune  
432 condition<sup>33</sup>. On the other hand, seroconversion was thought to be when the titer of  
433 neutralizing results increased 4 times with respect to the pre-immune condition.  
434 The expression of Activation-Induced Markers (AIM) by T cells and the number of  
435 Spot Forming Cells (SFC) for IFN- $\gamma$  were determined by ELISPOT and were  
436 evaluated by flow cytometry in a subgroup of 46 volunteers as previously  
437 described<sup>12,13,18</sup>. Briefly, PBMCs were stimulated with mega-pools (MPs) of peptides  
438 derived from SARS-CoV-2: MP-S, MP-R, MP-CD8-A, MP-CD8-B, Delta, and  
439 Omicron for 24h or 48h for flow cytometry and ELISPOT respectively. Then, 3-5 x  
440 10<sup>5</sup> cells were plated and stimulated with MP-S, MP-R, MP-CD8A, MP-CD8B,  
441 DMSO (negative control), or Phorbol-12-acetate (1.62mM) (Sigma,  
442 #P8139)/Ionomycin (0.6mM) (Sigma #I0634)<sup>22</sup>. Antibodies used to identify  
443 AIM<sup>+</sup>CD4<sup>+</sup> and AIM<sup>+</sup>CD8<sup>+</sup> T cells by flow cytometry are detailed in supplementary  
444 table 7. Samples were analyzed in a BD LSR-FORTESSA flow cytometer located in  
445 the flow cytometry core at the Pontificia Universidad Católica de Chile. For  
446 AIM<sup>+</sup>CD4<sup>+</sup> and AIM<sup>+</sup>CD8<sup>+</sup> T cells analyses, the percentage of DMSO was subtracted  
447 from each stimulated sample to subtract the background. The positivity threshold for

448 AIM<sup>+</sup>CD4<sup>+</sup> T cell stimulated with MP-S (0.174%) and MP-S+R (0.36%), as well as  
449 AIM<sup>+</sup>CD8<sup>+</sup> T cell stimulated with MP-CD8A+B (0.66%) was calculated using the  
450 median twofold standard deviation of each sample of the pre-immune group<sup>22,34</sup>.  
451 For ELISPOT, IFN- $\gamma$  was measured using a Immunospot<sup>®</sup> (#hIFNgIL-4M-10)  
452 following the manufacturer's instructions. Plates were read in an Immunospot S6  
453 Micro Analyzer. The positivity threshold for PBMCs stimulated with MP-S (19.31  
454 #SFC) MP-S+R (41.48 #SFC), as well as PBMCs stimulated with MP-CD8A+B  
455 (104.54 #SFC) was calculated using the median twofold standard deviation of each  
456 sample of the pre-immune group.

457

#### 458 Ethical considerations.

459 The current study protocol was reviewed and approved by the Institutional Scientific  
460 Ethical Committee of Health Sciences at the Pontificia Universidad Católica de Chile  
461 (#200708006) and the trial was approved by the Chilean Public Health Institute  
462 (#24204/20) and conducted according to the current Tripartite Guidelines for Good  
463 Clinical Practices, the Declaration of Helsinki, and local regulations. Informed  
464 consent was obtained from all volunteers upon enrollment.

465

#### 466 Statistical analyses

467 To statistically compare the neutralizing response against WT SARS-CoV-2,  
468 ANOVA with the Geisser-Greenhouse correction test followed by Sidak multiple tests  
469 were carried out on the log transformed data. Percentage of AIM<sup>+</sup>CD4<sup>+</sup> and  
470 AIM<sup>+</sup>CD8<sup>+</sup> T cells and IFN- $\gamma$  production by stimulated PBMCs against WT SARS-

471 CoV-2 were compared with a non-parametric Friedman test followed by a Dunn's  
472 test for multiple comparisons. To compare the neutralizing and the cellular  
473 responses against WT, Delta and Omicron, a two-way ANOVA test followed by a  
474 Dunn's test for multiple comparisons was used.

475 The significance level was set at 0.05 for all the analyses. All data were analyzed  
476 with GraphPad Prism 9.3.1.

477

#### 478 **Funding**

479 The CoronaVac03CL Study was funded by The Ministry of Health, Government of  
480 Chile, the Confederation of Production and Commerce (CPC), Chile and SINOVAC  
481 Biotech. NIH NIAID, under Contract 75N93021C00016, supports AS and Contract  
482 75N9301900065 supports AS, AG and DW. The Millennium Institute on Immunology  
483 and Immunotherapy, **Agencia Nacional de Investigación y Desarrollo (ANID)**  
484 **– Millennium Science Initiative Program – ICN09\_016 / ICN**  
485 **2021\_045: Millennium Institute on Immunology and Immunotherapy**  
486 **(ICN09\_016 / ICN 2021\_045; former P09/016-F)** supports SMB, KA, PAG and AMK;  
487 The Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0)  
488 supports SMB, PAG and AMK.

489

#### 490 **Competing interests**

491 GZ and WM are SINOVAC Biotech employees and contributed to the  
492 conceptualization of the study (clinical protocol and eCRF design) and did not  
493 participate in the analysis or interpretation of the data presented in the manuscript.

494 A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna,

495 AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group,  
496 RiverVest, MedaCorp, and Guggenheim. La Jolla Institute for Immunology (LJI) has  
497 filed for patent protection for various aspects of T cell epitope and vaccine design  
498 work. All other authors declare no conflict of interest.

499

## 500 **Acknowledgments**

501 We would like to thank the support of the Ministry of Health, Government of Chile;  
502 Ministry of Science, Technology, Knowledge, and Innovation, Government of Chile;  
503 The Ministry of Foreign Affairs, Government of Chile, and the Chilean Public Health  
504 Institute (ISP). We also would like to thank Rami Scharf, Jessica White, Jorge Flores  
505 and Miren Iturriza-Gomara from PATH for their active support in experimental design  
506 and scientific discussion. We also thank the Vice Presidency of Research (VRI), the  
507 Direction of Technology Transfer and Development (DTD) and the Legal Affairs  
508 Department (DAJ) of the Pontificia Universidad Católica de Chile. We are grateful to  
509 the Administrative Directions of the School of Biological Sciences and the School of  
510 Medicine of the Pontificia Universidad Católica de Chile for their administrative  
511 support. We would also like to thank to the members of the independent data safety  
512 monitoring committee (members in the SA) for their oversight, and finally to the  
513 subjects enrolled in the study for their participation and commitment with this trial.  
514 This project has been funded in whole or in part with Federal funds from the National  
515 Institute of Allergy and Infectious Diseases, National Institutes of Health, Department  
516 of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and  
517 Contract No. 75N93019C00065 to A.S and D.W.

518

519 **Author contributions.**

520 **Conceptualization:** AMK, KA, SMB, PAG, JVG, GZ, WM, FM-G, CM, HFP, BMS.

521 **Visualization:** AMK, KA, SMB, PAG, JVG, GZ, WM.

522 **Methodology and research:** FM-G, CM, HFP, BMS, AP-I, MR, DM-T, PP-S, DL,

523 CO, CC, NMSG, JAS, LFD, DR-P, YV, AC, SB, CI, MU, MSN, AR, RF, JF, JM, ER,

524 AG-A, MA, FV-E, RS-R, DW, AG, AS, GZ, WM, JVG-A

525 **Data analysis:** FM-G, CM, HFP, BMS, AP-I, MR, DM-T, LFD, AG-A, MA, FV-E, RS-

526 R

527 **Funding acquisition:** AMK, SMB.

528 **Project administration:** AMK, KA, SMB, PAG.

529 **Supervision:** AMK, KA, SMB, PAG.

530 **Writing – original draft:** FM-G, CM, HFP, BMS.

531 **Writing – review & editing:** AMK, SMB, PAG, FM-G, CM, HFP, BMS.

532 **Verifying underlying data:** AMK, SMB, FM-G, CM, HFP, BMS.

533

534 Members of the CoronaVac03CL study group are listed in the supplementary

535 material

536



537 **References.**

- 538 1. Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser,  
539 J., Bolland, W.H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022). Considerable  
540 escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature* *602*, 671-675.  
541 10.1038/s41586-021-04389-z.
- 542 2. Levin, E.G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R.,  
543 Asraf, K., Mendelson, E., Ziv, A., et al. (2021). Waning Immune Humoral Response to  
544 BNT162b2 Covid-19 Vaccine over 6 Months. *N Engl J Med* *385*, e84.  
545 10.1056/NEJMoa2114583.
- 546 3. Nagy, A., and Alhatlani, B. (2021). An overview of current COVID-19 vaccine  
547 platforms. *Comput Struct Biotechnol J* *19*, 2508-2517. 10.1016/j.csbj.2021.04.061.
- 548 4. Magen, O., Waxman, J.G., Makov-Assif, M., Vered, R., Dicker, D., Hernan, M.A.,  
549 Lipsitch, M., Reis, B.Y., Balicer, R.D., and Dagan, N. (2022). Fourth Dose of BNT162b2  
550 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med* *386*, 1603-1614.  
551 10.1056/NEJMoa2201688.
- 552 5. Reyes, H., Diethelm-Varela, B., Mendez, C., Rebolledo-Zelada, D., Lillo-Dapremont,  
553 B., Munoz, S.R., Bueno, S.M., Gonzalez, P.A., and Kalergis, A.M. (2022). Contribution  
554 of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU  
555 Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized  
556 Additive Models for Location, Scale, and Shape. *Front Public Health* *10*, 815036.  
557 10.3389/fpubh.2022.815036.
- 558 6. Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z.,  
559 et al. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2.  
560 *Science* *369*, 77-81. 10.1126/science.abc1932.
- 561 7. Chen, Z., Zheng, W., Wu, Q., Chen, X., Peng, C., Tian, Y., Sun, R., Dong, J., Wang, M.,  
562 Zhou, X., et al. (2022). Global diversity of policy, coverage, and demand of COVID-19  
563 vaccines: a descriptive study. *BMC Med* *20*, 130. 10.1186/s12916-022-02333-0.
- 564 8. Tanriover, M.D., Doganay, H.L., Akova, M., Guner, H.R., Azap, A., Akhan, S., Kose, S.,  
565 Erdinc, F.S., Akalin, E.H., Tabak, O.F., et al. (2021). Efficacy and safety of an  
566 inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a  
567 double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet* *398*,  
568 213-222. 10.1016/S0140-6736(21)01429-X.
- 569 9. Han, B., Song, Y., Li, C., Yang, W., Ma, Q., Jiang, Z., Li, M., Lian, X., Jiao, W., Wang, L.,  
570 et al. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2  
571 vaccine (CoronaVac) in healthy children and adolescents: a double-blind,  
572 randomised, controlled, phase 1/2 clinical trial. *Lancet Infect Dis* *21*, 1645-1653.  
573 10.1016/S1473-3099(21)00319-4.
- 574 10. Seyahi, E., Bakhdiyarli, G., Oztas, M., Kuskucu, M.A., Tok, Y., Sut, N., Ozcifci, G.,  
575 Ozcaglayan, A., Balkan, I., Saltoglu, N., et al. (2021). Antibody response to inactivated  
576 COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study  
577 among hospital workers and elderly. *Rheumatol Int* *41*, 1429-1440. 10.1007/s00296-  
578 021-04910-7.

- 579 11. Jara, A., Undurraga, E.A., Gonzalez, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A.,  
580 Acevedo, J., Leo, K., Leon, F., et al. (2021). Effectiveness of an Inactivated SARS-CoV-  
581 2 Vaccine in Chile. *N Engl J Med* 385, 875-884. [10.1056/NEJMoa2107715](https://doi.org/10.1056/NEJMoa2107715).
- 582 12. Bueno, S.M., Abarca, K., Gonzalez, P.A., Galvez, N.M.S., Soto, J.A., Duarte, L.F.,  
583 Schultz, B.M., Pacheco, G.A., Gonzalez, L.A., Vazquez, Y., et al. (2021). Safety and  
584 Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy  
585 Adults in Chile. *Clin Infect Dis*. [10.1093/cid/ciab823](https://doi.org/10.1093/cid/ciab823).
- 586 13. Melo-Gonzalez, F., Soto, J.A., Gonzalez, L.A., Fernandez, J., Duarte, L.F., Schultz,  
587 B.M., Galvez, N.M.S., Pacheco, G.A., Rios, M., Vazquez, Y., et al. (2021). Recognition  
588 of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2  
589 Inactivated Vaccine. *Front Immunol* 12, 747830. [10.3389/fimmu.2021.747830](https://doi.org/10.3389/fimmu.2021.747830).
- 590 14. Falsey, A.R., Frenck, R.W., Jr., Walsh, E.E., Kitchin, N., Absalon, J., Gurtman, A.,  
591 Lockhart, S., Bailey, R., Swanson, K.A., Xu, X., et al. (2021). SARS-CoV-2 Neutralization  
592 with BNT162b2 Vaccine Dose 3. *N Engl J Med* 385, 1627-1629.  
593 [10.1056/NEJMc2113468](https://doi.org/10.1056/NEJMc2113468).
- 594 15. Choi, A., Koch, M., Wu, K., Chu, L., Ma, L., Hill, A., Nunna, N., Huang, W., Oestreicher,  
595 J., Colpitts, T., et al. (2021). Safety and immunogenicity of SARS-CoV-2 variant mRNA  
596 vaccine boosters in healthy adults: an interim analysis. *Nat Med* 27, 2025-2031.  
597 [10.1038/s41591-021-01527-y](https://doi.org/10.1038/s41591-021-01527-y).
- 598 16. Pegu, A., O'Connell, S.E., Schmidt, S.D., O'Dell, S., Talana, C.A., Lai, L., Albert, J.,  
599 Anderson, E., Bennett, H., Corbett, K.S., et al. (2021). Durability of mRNA-1273  
600 vaccine-induced antibodies against SARS-CoV-2 variants. *Science* 373, 1372-1377.  
601 [10.1126/science.abj4176](https://doi.org/10.1126/science.abj4176).
- 602 17. Moreira, E.D., Jr., Kitchin, N., Xu, X., Dychter, S.S., Lockhart, S., Gurtman, A., Perez,  
603 J.L., Zerbini, C., Dever, M.E., Jennings, T.W., et al. (2022). Safety and Efficacy of a  
604 Third Dose of BNT162b2 Covid-19 Vaccine. *N Engl J Med* 386, 1910-1921.  
605 [10.1056/NEJMoa2200674](https://doi.org/10.1056/NEJMoa2200674).
- 606 18. Schultz, B.M., Melo-Gonzalez, F., Duarte, L.F., Galvez, N.M.S., Pacheco, G.A., Soto,  
607 J.A., Berrios-Rojas, R.V., Gonzalez, L.A., Moreno-Tapia, D., Rivera-Perez, D., et al.  
608 (2022). A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells  
609 that Recognize Delta and Omicron Variants of Concern. *mBio*, e0142322.  
610 [10.1128/mbio.01423-22](https://doi.org/10.1128/mbio.01423-22).
- 611 19. Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S.,  
612 Meltzer, L., Asraf, K., Cohen, C., Fluss, R., et al. (2022). Efficacy of a Fourth Dose of  
613 Covid-19 mRNA Vaccine against Omicron. *N Engl J Med* 386, 1377-1380.  
614 [10.1056/NEJMc2202542](https://doi.org/10.1056/NEJMc2202542).
- 615 20. Duarte, L.F., Galvez, N.M.S., Iturriaga, C., Melo-Gonzalez, F., Soto, J.A., Schultz, B.M.,  
616 Urzua, M., Gonzalez, L.A., Vazquez, Y., Rios, M., et al. (2021). Immune Profile and  
617 Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-  
618 CoV-2 Vaccine. *Front Immunol* 12, 742914. [10.3389/fimmu.2021.742914](https://doi.org/10.3389/fimmu.2021.742914).
- 619 21. Abarca, K., Iturriaga, C., Urzua, M., Le Corre, N., Pineda, A., Fernandez, C.,  
620 Dominguez, A., Gonzalez, P.A., Bueno, S.M., Donato, P., et al. (2022). Safety and  
621 Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-

- 622 CoV-2 Vaccine in Adults: A Randomized Clinical Trial. *Vaccines (Basel)* 10.  
623 10.3390/vaccines10071082.
- 624 22. Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R.,  
625 Rawlings, S.A., Sutherland, A., Premkumar, L., Jadi, R.S., et al. (2020). Targets of T  
626 Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and  
627 Unexposed Individuals. *Cell* 181, 1489-1501 e1415. 10.1016/j.cell.2020.05.015.
- 628 23. Arbel, R., Sergienko, R., Friger, M., Peretz, A., Beckenstein, T., Yaron, S., Netzer, D.,  
629 and Hammerman, A. (2022). Effectiveness of a second BNT162b2 booster vaccine  
630 against hospitalization and death from COVID-19 in adults aged over 60 years. *Nat*  
631 *Med* 28, 1486-1490. 10.1038/s41591-022-01832-0.
- 632 24. Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H.M., Selvaraj,  
633 M., Liu, C., Mentzer, A.J., Supasa, P., Duyvesteyn, H.M.E., et al. (2022). Antibody  
634 escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. *Cell*  
635 185, 2422-2433 e2413. 10.1016/j.cell.2022.06.005.
- 636 25. Hurme, A., Jalkanen, P., Heroum, J., Lienes, O., Vara, S., Melin, M., Terasjarvi, J., He,  
637 Q., Poysti, S., Hanninen, A., et al. (2022). Long-Lasting T Cell Responses in BNT162b2  
638 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients. *Front Immunol* 13,  
639 869990. 10.3389/fimmu.2022.869990.
- 640 26. Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I.,  
641 Goodwin, B., Phillips, E., Mallal, S., et al. (2022). SARS-CoV-2 vaccination induces  
642 immunological T cell memory able to cross-recognize variants from Alpha to  
643 Omicron. *Cell* 185, 847-859 e811. 10.1016/j.cell.2022.01.015.
- 644 27. Zhang, Z., Mateus, J., Coelho, C.H., Dan, J.M., Moderbacher, C.R., Galvez, R.I., Cortes,  
645 F.H., Grifoni, A., Tarke, A., Chang, J., et al. (2022). Humoral and cellular immune  
646 memory to four COVID-19 vaccines. *Cell* 185, 2434-2451 e2417.  
647 10.1016/j.cell.2022.05.022.
- 648 28. Escobar, A., Reyes-Lopez, F.E., Acevedo, M.L., Alonso-Palomares, L., Valiente-  
649 Echeverria, F., Soto-Rifo, R., Portillo, H., Gatica, J., Flores, I., Nova-Lamperti, E., et al.  
650 (2021). Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule  
651 Vaccination in a Healthy Population Group. *Front Immunol* 12, 766278.  
652 10.3389/fimmu.2021.766278.
- 653 29. Mok, C.K.P., Cohen, C.A., Cheng, S.M.S., Chen, C., Kwok, K.O., Yiu, K., Chan, T.O., Bull,  
654 M., Ling, K.C., Dai, Z., et al. (2022). Comparison of the immunogenicity of BNT162b2  
655 and CoronaVac COVID-19 vaccines in Hong Kong. *Respirology* 27, 301-310.  
656 10.1111/resp.14191.
- 657 30. Reynolds, C.J., Swadling, L., Gibbons, J.M., Pade, C., Jensen, M.P., Diniz, M.O.,  
658 Schmidt, N.M., Butler, D.K., Amin, O.E., Bailey, S.N.L., et al. (2020). Discordant  
659 neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2  
660 infection. *Sci Immunol* 5. 10.1126/sciimmunol.abf3698.
- 661 31. Galipeau, Y., Siragam, V., Laroche, G., Marion, E., Greig, M., McGuinty, M., Booth,  
662 R.A., Durocher, Y., Cuperlovic-Culf, M., Bennett, S.A.L., et al. (2021). Relative Ratios  
663 of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-  
664 Neutralization of SARS-CoV-2 Spike Binding to ACE2. *EBioMedicine* 74, 103700.  
665 10.1016/j.ebiom.2021.103700.

- 666 32. Beltran-Pavez, C., Riquelme-Barríos, S., Oyarzun-Arrau, A., Gaete-Argel, A.,  
667 Gonzalez-Stegmaier, R., Cereceda-Solis, K., Aguirre, A., Travisany, D., Palma-Vejares,  
668 R., Barriga, G.P., et al. (2021). Insights into neutralizing antibody responses in  
669 individuals exposed to SARS-CoV-2 in Chile. *Sci Adv* 7. 10.1126/sciadv.abe6855.
- 670 33. Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W.,  
671 et al. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2  
672 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-  
673 controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 21, 181-192. 10.1016/S1473-  
674 3099(20)30843-4.
- 675 34. Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., Grifoni, A., Ramirez,  
676 S.I., Haupt, S., Frazier, A., et al. (2021). Immunological memory to SARS-CoV-2  
677 assessed for up to 8 months after infection. *Science* 371. 10.1126/science.abf4063.
- 678
- 679

680 **Figure legends.**

681

682 **Figure 1. Study profile, vaccination scheme and sampling, enrolled volunteers,**  
683 **and cohort included in the study.** (A) Schematic representation and sample  
684 distribution of performed experiments. From a total of 138 individuals that received  
685 two booster doses of CoronaVac®, the neutralizing antibodies were analyzed in  
686 blood samples from 87 volunteers by surrogate virus neutralization test (sVNT), 63  
687 by conventional virus neutralization test (cVNT) and 60 by Pseudovirus-based  
688 neutralization assay (pVNT). sVNT and pVNT were used to evaluate the neutralizing  
689 response induced by a second booster dose against the Delta and/or the Omicron  
690 variants. Cellular immunity was analyzed in blood samples from 46 volunteers at  
691 each time point. (B) Blood sampling times, before the first vaccination/pre-immune  
692 (T1), at 4 weeks (+3 weeks) after the second dose (T2), before the administration of  
693 the third dose (-9 weeks) (T3), at 4 weeks (-1/+2 weeks) after the third dose (T4),  
694 before the administration of the fourth dose (-9 weeks) (T5) and at 4 weeks (+5  
695 weeks) after the fourth dose (T6), and vaccination schedule.

696

697 **Figure 2. Humoral response of volunteers who received a second booster dose**  
698 **of CoronaVac®.** The neutralizing capacity of circulating antibodies in adults was  
699 evaluated in Blood samples collected before the first vaccination/pre-immune (T1),  
700 at 4 weeks (+3 weeks) after the second dose (T2), before the administration of the  
701 third dose (-9 weeks) (T3), at 4 weeks (-1/+2 weeks) after the third dose (T4), before  
702 the administration of the fourth dose (-9 weeks) (T5) and at 4 weeks (+5 weeks) after  
703 the fourth dose (T6), and vaccination schedule. (A) Neutralizing capacity of

704 circulating antibodies against SARS-CoV-2 in serum of 87 volunteers was  
705 determined by a surrogate Viral Neutralization Test (sVNT) expressed as IU/ml. (B)  
706 Reciprocal dilution of sera required to prevent in vitro infection obtained sera from  
707 63 adults required to prevent in vitro infection of Hela Cells. Numbers on top of each  
708 data set represents the GMT, and horizontal lines represent the 95% CI. (C)  
709 Geometric mean titer (GMTs) of neutralizing antibodies against the WT-spike, Delta-  
710 spike and Omicron-spike proteins detected in the serum of 87 volunteers immunized  
711 with CoronaVac® through sVNT. Dashed line: limit of detection. Red values under  
712 the significance line: indicate a decrease in the means of the two compared time  
713 points; Blue values: indicate an increase in the means of the two compared time  
714 points. (A-B) Data was analyzed with ANOVA with the Geisser-Greenhouse  
715 correction test followed by a post-hoc Sidak multiple test. \*P<0.05; \*\*P<0.01;  
716 \*\*\*P<0.001; \*\*\*\*P<0.0001. (C) Two-way ANOVA test followed by a post-hoc Dunn's  
717 multiple test. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001, \*\*\*\*P<0.0001.

718

719 **Figure 3. Cellular response of volunteers that received a second booster dose**  
720 **of CoronaVac®.** Cellular response in adults was evaluated in PBMCs collected  
721 before the first vaccination/pre-immune (T1), at 4 weeks (+3 weeks) after the second  
722 dose (T2), before the administration of the third dose (-9 weeks) (T3), at 4 weeks (-  
723 1/+2 weeks) after the third dose (T4), before the administration of the fourth dose (-  
724 9 weeks) (T5) and at 4 weeks (+5 weeks) after the fourth dose (T6), and vaccination  
725 schedule. (A) The percentage of AIM+ (OX40+CD137+) CD4+ T cells and (B) AIM+  
726 (CD69+CD137+) CD8+ T cells was determined in PBMCs of 46 adult volunteers by  
727 flow cytometry. PBMCs were stimulated for 24h with mega-pools of peptides derived


728 from proteins of WT SARS-CoV-2. The number of IFN-g producing SFCs was  
729 determined by ELISPOT upon stimulation for 48h with mega-pools of (C) S+R  
730 peptides or with (D) CD8A+B peptides. (E) The percentage of AIM+  
731 (OX40+CD137+) CD4+ T cells from PBMCs of 46 adult volunteers were analyzed  
732 by flow cytometry after the stimulation for 24h with mega-pools of peptides derived  
733 from the Spike protein of the WT SARS-CoV-2, the Delta and the Omicron variants.  
734 (F) The number of IFN-g producing SFCs was determined by ELISPOT assays  
735 PBMCs of 46 adult volunteers were analyzed by flow cytometry after the stimulation  
736 for 48h with mega-pools of peptides derived from the Spike protein of the WT SARS-  
737 CoV-2, the Delta and the Omicron variants. Horizontal lines represent mean and  
738 95% CI. Flow cytometry data was normalized against the DMSO control. (A-D) Data  
739 was analyzed using a non-parametric Friedman test followed by a post-hoc Dunn's  
740 test for multiple comparisons. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001; \*\*\*\*P<0.0001. (E-F)  
741 Two-way ANOVA test followed by a post-hoc Dunn's multiple test. \*P<0.05;  
742 \*\*P<0.01; \*\*\*P<0.001, \*\*\*\*P<0.0001.

743


744

745

A












B





medRxiv preprint doi: <https://doi.org/10.1101/2022.08.22.22279080>; this version posted August 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).





**Table 1: Frequency of volunteers with detectable T cell response against WT SARS-CoV-2**

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.22.23271061>; this version posted October 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Methodology	Indicators Cellular positivity	T1	T2	T3	T4	T5	T6
Flow cytometry	CD4 <sup>+</sup> AIM <sup>+</sup> (OX40 <sup>+</sup> CD13)	6/46	16/46	23/46	30/46	19/46	21/46
	%	13.0	34.8	50.0	65.2	41.3	45.7
	CD8 <sup>+</sup> AIM <sup>+</sup> (CD69 <sup>+</sup> CD13)	6/46	16/46	10/46	16/46	10/46	12/46
	%	13.0	34.8	21.7	34.8	21.7	26.1
	IFN- $\gamma$ <sup>+</sup> SFC MP-S+R	8/46	22/46	21/46	31/46	24/46	23/46
	%	17.4	47.8	45.7	67.4	52.2	50
ELISPOT	IFN- $\gamma$ <sup>+</sup> SFC MP- CD8A+B	2/46	3/46	5/46	7/46	8/46	6/46
	%	4.3	6.5	10.9	15.2	17.4	13.0

AIM: Activation-Induced-Marker; SFC: Spot Forming Cells; MP-S: Spike mega-pool of peptides